Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2022-08-08 Investor Presentation
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
PYC Therapeutics Investor Call - 18 August 2022 2 pages 191.0KB
Investor Presentation Classification · 95% confidence The document is an announcement dated 9 August 2022 about PYC Therapeutics hosting an investor presentation and conference call on 18 August 2022. It provides details about the event, including the time, location, registration link, and the topics to be discussed (progress update and outlook). There are no financial statements or detailed financial data included. The document is primarily an invitation and informational notice about an upcoming investor call and presentation, not the transcript or the presentation itself. Therefore, it fits the category of a Call Transcript (CT) only if it contained the transcript, but since it is an announcement of the event, it is best classified as an Investor Presentation (IP) announcement. Given the content focuses on the investor presentation and conference call, the most appropriate classification is Investor Presentation (IP). The document length is 4317 characters, which is consistent with an announcement rather than a full report or transcript.
2022-08-08 English
Change of Director's Interest Notice 2 pages 277.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details the change in securities holdings of a company director, including the number of shares held before and after the change, the nature of the interest, and the transaction details. This matches the definition of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document length is 3382 characters, which is consistent with a detailed notice rather than a full report or announcement. Therefore, the appropriate classification is Director's Dealing (DIRS).
2022-08-03 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 240.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'REPORT FOR THE QUARTER ENDED 30 June 2022 (Q2)' and contains detailed information about the company's drug development pipeline, progress updates, and financial data including a quarterly cash flow report (Appendix 4C). The presence of substantive financial data and analysis for a quarter, along with operational updates, indicates this is a comprehensive quarterly report. It is not merely an announcement or a brief summary but includes detailed financial and operational information for the quarter ended June 30, 2022. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2022
2022-07-26 English
Share Trading Policy 8 pages 353.2KB
Director's Dealing Classification · 95% confidence The document is titled 'Share Trading Policy' and details guidelines and rules for trading securities by Key Management Personnel of PYC Therapeutics. It discusses insider trading prohibitions, trading windows, approval and notification requirements for trades by directors and executives. There is no financial data, earnings information, or report content. It is a policy document related to insider trading and securities transactions by company insiders. This fits the definition of Director's Dealing (DIRS), which covers reports or policies related to personal share transactions by company directors and executives. The document is not an announcement of a transaction but a policy document governing such transactions. Therefore, the appropriate classification is DIRS with high confidence.
2022-06-27 English
Corporate Presentation - May 2022 18 pages 700.7KB
Investor Presentation Classification · 95% confidence The document is titled 'Corporate Presentation' and dated May 2022. It contains detailed information about the company's business, pipeline programs, market opportunities, scientific data, management team, and upcoming milestones. The content is structured as a presentation with slides, images, and charts, focusing on the company's strategy, technology, and clinical development plans. There are no full financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not an earnings release, audit report, or regulatory filing. It is clearly a detailed presentation aimed at investors or stakeholders to update them on the company's progress and outlook. Therefore, the document fits the category of an Investor Presentation (IP).
2022-05-30 English
PYC Q2 Investor Call - 31 May 2022 2 pages 188.9KB
Regulatory Filings Classification · 95% confidence The document is an announcement dated 27 May 2022 from PYC Therapeutics about hosting a Q2 investor call on 31 May 2022. It provides details about the call, including registration information, topics to be discussed, and company background. There are no financial statements, detailed financial data, or comprehensive report content included. The document is short (4088 characters) and serves as a notice for an upcoming event rather than a transcript or report. Therefore, it fits the category of a Call Transcript announcement or invitation rather than the transcript itself. However, since it is an announcement of the call and not the transcript, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories more specifically. Confidence is high due to clear identification of the document as an event announcement without substantive financial or report content.
2022-05-26 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.